BRCA1 and ovarian cancer: An overall survival (OS) advantage was observed with olaparib for PSR ovarian cancer patients irrespective of BRCA1/2 mutation status in the updated survival data of Study19, while the median OS in BRCAmt ovarian cancer was longer than that in the BRCAwt subgroups [10].